ClinicalTrials.gg
CompletedNCT03557918Updated Jul 3, 2024Results posted

Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer

A Phase 2 interventional study of Tremelimumab in Urothelial Carcinoma, sponsored by Matthew Galsky. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-03.

Sponsored by Matthew Galsky · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 141 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Enrollment
227th of 333
26 · median 46
Started
2018
with 32 others
Phase 2
110 of 361
18 open now
Registered
144th of 361
by date

Among the 361 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 227th largest by enrollment of the 333 interventional ones that give a count, is one of 33 that started in 2018, is one of 110 in phase 2, and was the 144th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 361 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

This is a phase II trial designed to estimate the activity of single agent tremelimumab in subjects with metastatic urothelial cancer with disease progression despite prior treatment with PD-1/PD-L1 blockade. The primary endpoint is objective response rate and the study will employ a Simon's 2-stage design.

03

Conditions studied

  • Urothelial Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
  • Performance Status of 0 or 1 within 14 days prior to registration.
  • or cytologically documented urothelial cancer. Locally advanced (T4b, any N; or any T, N 2-3) or disease (M1, Stage IV) (also termed TCC or UCC of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra). Subjects with mixed histologies are eligible provided that the predominant component is urothelial cancer. Locally advanced bladder cancer must be inoperable on the basis of involvement of pelvic sidewall or adjacent viscera (clinical Stage T4b) or bulky nodal metastasis (N2-N3).
  • Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides. If is not available and the subject is undergoing a standard of care biopsy, tissue from the biopsy is required to be submitted for correlative analyses. Subjects without adequate baseline tumor tissue may be considered for enrollment on a case by case basis after discussion with the sponsor-investigator.
  • according to 1.1 within 28 days prior to registration. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes, which must have short axis ≥15 mm) with computed tomography (CT) (preferred) or magnetic resonance imaging (MRI) scans, preferably with IV contrast, and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines; lesions in a previously irradiated field can be used as a measurable disease provided that there has been demonstrated progression in the lesion.
  • A subject with prior may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study registration, have been off of for ≥ 2 weeks, and are asymptomatic
  • Subjects must have progressed despite prior treatment with /PD-L1 antibody therapy. In addition, subjects must meet the following criteria:

    • Subjects must not have progressed within 2 months of starting prior anti-PD-1/PD-L1 antibody therapy.
    • Subjects must have received at least 1 line of prior systemic therapy
    • Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
    • All AEs while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study with the exception of endocrine related AEs that are stable on replacement therapy (e.g., steroids, thyroid hormone) which may be considered eligible but must be discussed with the sponsor-investigator.
    • Must not have experienced a ≥ Grade 3 immune related AE or an immune related neurologic (neuro-muscular) or ocular AE of any grade while receiving prior immunotherapy. NOTE: Subjects with endocrine AE of ≤ Grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic. Must not have required the use of additional other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day.
    • Patients with Gr 3 /ALT elevation \< 8 fold that resolved with steroids without additional immunosuppression can be included (Patients who experienced Hy's law on PD-1/L1 therapy will be excluded)
  • Prior cancer treatment must be completed at least 28 days or 5 half-lives (whichever is shorter) prior to first dose of study drug. Subjects must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or baseline.
  • Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 14 days prior to registration.
  • (ANC) ≥ 1500/mm3
  • (Hgb) ≥ 9 g/dL
  • Renal
  • Calculated ≥ 30 cc/min OR
  • Creatinine ≤ 1.5
  • ≤ 1.5 × (ULN); This will not apply to
  • Aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 x ULN for subjects with hepatic metastases
  • Alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 x ULN for subjects with hepatic metastases
  • Evidence of status or negative urinary or serum pregnancy test for female premenopausal subjects. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:
  • Females of who are sexually active with a non-sterilized male partner must be willing to abstain from heterosexual activity or to use 1 highly of effective method of from the time of informed consent until 90 days after the last dose of tremelimumab. Non-sterilized male partners of a female patient must use male condom plus spermicide throughout this period. See Table 2 for acceptable contraceptive methods.
  • Non-sterilized males who are sexually active with a female partner of childbearing potential must use a male condom plus spermicide from screening through 90 days after receipt of the final dose of tremelimumab. Female partners (of childbearing potential) of male subjects must also use a highly effective method of contraception throughout this period

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).
  • Known additional that is active and/or progressive requiring treatment. Patients with incidental histologic findings of prostate cancer (tumor/node/ stage of T1a or T1b or prostate-specific antigen \<10) who have not received hormonal treatment may be included, pending a discussion with the sponsor-investigator
  • Treatment with any drug within 28 days prior to registration.
  • Prior treatment with an antibody
  • Any unresolved toxicity National Cancer Institute (NCI) Version 4.03 Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and laboratory values defined in the inclusion criteria.

    • Subjects with Grade ≥ 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Sponsor Investigator
    • Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with tremelimumab (e.g., hearing loss) may be included after consultation with the sponsor-investigator
  • Any concurrent chemotherapy, investigational product, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (e.g., hormone replacement therapy) is acceptable. Note: Local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g., local surgery or radiotherapy)
  • Radiation therapy within 14 days of first dose of study drug
  • Major surgical procedure within 28 days prior to first dose of study treatment
  • History of allogeneic organ transplantation that requires use of agents
  • Active or prior documented of inflammatory disorders (including but not limited to inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc). The following are exceptions to this criterion:

    • Subjects with vitiligo
    • Subjects with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Subjects without active disease in the last5 years may be considered for enrollment after discussion with the sponsor-investigator
    • Subjects with celiac disease controlled by diet alone may be considered for enrollment after discussion with the sponsor-investigator
  • corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms calculated. Any abnormalities detected require triplicate results and a mean QTcF \<470 ms calculated from 3 ECGs obtained over a brief period (eg, 30 minutes)
  • Past medical history of Interstitial Lung Disease (ILD), drug-induced ILD, radiation pneumonitis which required treatment, or any evidence of clinically active interstitial lung disease.
  • History of active primary immunodeficiency
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Tremelimumab

    Tremelimumab 750 mg IV Day 1 of each 28 day cycle. Up to 7 cycles.

    Drug: Tremelimumab

Interventions

  • Tremelimumab 750 mg IV on Day 1 of each 28 day cycle; up to 7 cycles. Subjects that complete all initial 7 cycles but later progress during follow up may receive an additional 7 cycles of tremelimumab providing they meet eligibility criteria.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. ORR is defined as the proportion of all subjects with confirmed PR or CR according to RECIST 1.1.

    Time frame: Up to a maximum of 12 months

Secondary outcomes

  1. Adverse Events

    Number of participants with adverse events are reported according to the National Cancer Institute's Common Terminology Criteria for Adverse Events(CTCAE) version 4.

    Time frame: AE had been recorded from time of consent until 30 days after discontinuation of study drug or until a new anti-cancer treatment starts, whichever occurs first; up to a maximum of 13 months

  2. Disease Control Rate

    The disease control rate is defined as the percentage of patients who have achieved complete response, partial response and stable disease by RECIST 1.1

    Time frame: Up to a maximum of 12 months

  3. Duration of Response

    Duration of response (DoR) is defined as the time from randomization to disease progression or death in patients who achieve complete or partial response.

    Time frame: Up to a maximum of 24 months

  4. Progression Free Survival (PFS)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as time from registration until disease progression met by RECIST 1.1 or death from any cause.

    Time frame: Time of treatment start until the criteria for disease progression or death. Up to a maximum of 24 months.

  5. Overall Survival

    Overall survival is defined as the time from treatment start until death or date of last contact.

    Time frame: Time of treatment start until death or date of last contact, up to a maximum of 42 months.

07

Results

Posted Jul 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneTremelimumab
Started26
Completed26
Not completed0

Outcome measures

PrimaryObjective Response Rate

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. ORR is defined as the proportion of all subjects with confirmed PR or CR according to RECIST 1.1.

Time frame:
Up to a maximum of 12 months
Reported as:
Number · Percentage of participants
Objective Response Rate
Percentage of participantsTremelimumab
Objective Response Rate8.3
SecondaryAdverse Events

Number of participants with adverse events are reported according to the National Cancer Institute's Common Terminology Criteria for Adverse Events(CTCAE) version 4.

Time frame:
AE had been recorded from time of consent until 30 days after discontinuation of study drug or until a new anti-cancer treatment starts, whichever occurs first; up to a maximum of 13 months
Reported as:
Count of participants · Participants
Adverse Events
ParticipantsTremelimumab
Number of patients had at least one grade 3 or greater adverse event19
Number of patients had at least one grade 3 or greater treatment related adverse event11
Number of patients having serious adverse event14
SecondaryDisease Control Rate

The disease control rate is defined as the percentage of patients who have achieved complete response, partial response and stable disease by RECIST 1.1

Time frame:
Up to a maximum of 12 months
Reported as:
Number · Percentage of participants
Disease Control Rate
Percentage of participantsTremelimumab
Disease Control Rate29.17
SecondaryDuration of Response

Duration of response (DoR) is defined as the time from randomization to disease progression or death in patients who achieve complete or partial response.

Time frame:
Up to a maximum of 24 months
Reported as:
Median · Months
Duration of Response
MonthsTremelimumab
Duration of Response17.45 (10.91 to 23.98)
SecondaryProgression Free Survival (PFS)

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as time from registration until disease progression met by RECIST 1.1 or death from any cause.

Time frame:
Time of treatment start until the criteria for disease progression or death. Up to a maximum of 24 months.
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsTremelimumab
Progression Free Survival (PFS)1.83 (1.68 to 1.91)
SecondaryOverall Survival

Overall survival is defined as the time from treatment start until death or date of last contact.

Time frame:
Time of treatment start until death or date of last contact, up to a maximum of 42 months.
Reported as:
Median · Months
Overall Survival
MonthsTremelimumab
Overall Survival7.75 (5.39 to 15.44)

Adverse events

Collected over All-Cause Mortality was monitored up to a maximum of 42 months. Serious Adverse Events and Other (Not Including Serious) Adverse Events were monitored up to 13 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tremelimumab19/26 (73.1%)14/26 (53.8%)22/26 (84.6%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventTremelimumab
ACUTE KIDNEY INJURYRenal and urinary disorders3/26
DIARRHEAGastrointestinal disorders3/26
SEPSISInfections and infestations3/26
COLITISGastrointestinal disorders2/26
CREATININE INCREASEDInvestigations2/26
METABOLISM AND NUTRITION DISORDERS - OTHER, SPECIFYMetabolism and nutrition disorders2/26
ALANINE AMINOTRANSFERASE INCREASEDInvestigations1/26
BACK PAINMusculoskeletal and connective tissue disorders1/26
COLONIC OBSTRUCTIONGastrointestinal disorders1/26
ENCEPHALOPATHYNervous system disorders1/26
Most frequent other events
Showing 10 of 71
Most frequent other events
EventTremelimumab
FATIGUEGeneral disorders12/26
DIARRHEAGastrointestinal disorders11/26
HYPONATREMIAMetabolism and nutrition disorders9/26
ANEMIABlood and lymphatic system disorders8/26
NAUSEAGastrointestinal disorders8/26
CREATININE INCREASEDInvestigations7/26
ALKALINE PHOSPHATASE INCREASEDInvestigations6/26
ANOREXIAMetabolism and nutrition disorders6/26
LIPASE INCREASEDInvestigations5/26
PRURITUSSkin and subcutaneous tissue disorders5/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Tremelimumab
Median71 (48 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Tremelimumab
Female7
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Tremelimumab
Hispanic or Latino2
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Tremelimumab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American5
White19
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)Tremelimumab
United States26
Primary Tumor Site
Primary Tumor Site(Participants)Tremelimumab
Renal Pelvis6
Ureter2
Urinary Bladder18
08

Study locations

7 sites
  • Georgetown University
    Washington, District of Columbia 20057, United States
  • Winship Cancer Institute of Emory University
    Atlanta, Georgia 30322, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Westwood, Kansas 66205, United States
  • Dana Farber- Partners Cancer Care, Inc
    Boston, Massachusetts 02215, United States
  • Ichan School of Medicine at Mount Sinai
    New York, New York 10029-6542, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Huntsman Cancer Institute University of Utah
    Salt Lake City, Utah 84112, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Dec 2021, 36 months.

Results were first posted in Jul 2024, 2 years 6 months after primary completion.

Of 93 non-industry phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 102. This study's 36 months is below that.

Counting every sponsor, half of 121 studies reached it within 57 months; a quarter within 35 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2018
First posted
Jun 15, 2018
StartActual
Nov 12, 2018
Primary completionActual
Dec 6, 2021
CompletionActual
Jun 7, 2023
Results first posted
Jul 3, 2024
Last update
Jul 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03557918
Lead sponsor
Matthew Galsky
Collaborators
AstraZeneca
Responsible party
Matthew Galsky (Sponsor-Investigator, Hoosier Cancer Research Network) — Sponsor-investigator
First posted
Jun 15, 2018
Start date
Nov 12, 2018
Primary completion
Dec 6, 2021
Completion
Jun 7, 2023
Results posted
Jul 3, 2024
Last update
Jul 3, 2024

Study contacts

Matthew D Galsky, MD
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion